Document is current
Any future updates will be listed below
-
Authors
Kaltheuner, Ines H.
Anand, Kanchan
Moecking, Jonas
Düster, Robert https://orcid.org/0000-0003-4954-6883
Wang, Jinhua https://orcid.org/0000-0002-1214-4103
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Geyer, Matthias https://orcid.org/0000-0002-7718-5002
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GE 976/9-2, EXC2151–390873048)
Deutsche Krebshilfe (70114008)
- License Information
-
More Information
Article History
Received: 28 April 2021
Accepted: 28 October 2021
First Online: 16 November 2021
Competing interests
: N.S.G. is a founder, science advisory board member (SAB) and equity holder in Gatekeeper, Syros, Larkspur, Inception, C4, B2S, Allorion, Jengu, and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Arbella, Deerfield, Epiphanes, and Sanofi. The other authors declare no competing interests.
